Nomenclature for biosimilars; a continuing thorny issue

Author(s): Robin Thorpe, PhD, FRCPath

Abstract: Nomenclature for biosimilars is a controversial issue. In this issue of GaBI Journal, a paper by Sarshad et al. considers the US FDA’s published system for this and concludes that it will be a positive solution to a global issue. But this may be a premature judgement. Submitted: 1 January 2019; Revised: 3 January […]

Read more →